Tarsus is a late-stage biopharmaceutical company focused on developing therapies for ophthalmology conditions.
Tarsus’ lead pipeline candidate, TP-03, is attempting to treat Demodex blepharitis. This treatment has completed four phase 2 trials to date. It expects to launch a phase 2b/3 trial in September.
Tarsus was founded in 2016.
More articles on surgery centers:
12-OR ASC part of $295M Florida orthopedic hospital expansion
3 ASCs launching total joint programs
4 ASCs installing total joint robots
